331-61-3

Basic information

• Product Name: 3-FLUORO-4-METHOXYBENZYL BROMIDE
• Synonyms: 3-FLUORO-4-METHOXYBENZYL BROMIDE;3-Fluoro-4-methoxybenzyl bromide ,98%;4-(broMoMethyl)-2-fluoro-1-Methoxybenzene;4-(Bromomethyl)-2-fluoroanisole, 4-(Bromomethyl)-2-fluoro-1-methoxybenzene, 4-(Bromomethyl)-2-fluorophenyl methyl ether
• CAS NO: 331-61-3
• Molecular Formula: C₈H₈BrFO
• Molecular Weight: 219.05
• Product Categories: Fluorine series
• Mol File: 331-61-3.mol

Chemical Properties

• Melting Point: 44-46°C
• Boiling Point: 245.1 °C at 760 mmHg
• Flash Point: 121.6 °C
• Appearance: /
• Density: 1.488g/cm³
• Vapor Pressure: 0.0459mmHg at 25°C
• Refractive Index: 1.531
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Sensitive: Lachrymatory
• CAS DataBase Reference: 3-FLUORO-4-METHOXYBENZYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-FLUORO-4-METHOXYBENZYL BROMIDE(331-61-3)
• EPA Substance Registry System: 3-FLUORO-4-METHOXYBENZYL BROMIDE(331-61-3)

Safety Data

• Hazard Codes: C,Xn
• Statements: 36/37/38-52-22-34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN3261
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 331-61-3(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C8H8BrFO/c1-11-8-3-2-6(5-9)4-7(8)10/h2-4H,5H2,1H3

Upstream product

• 403-20-3 3-fluoro-p-anisic acid 
• 351-54-2 3-fluoro-p-anisaldehyde 
• 96047-32-4 3-fluoro-4-methoxybenzyl alcohol 
• 399-55-3 2-fluoro-1-methoxy-4-methylbenzene 
• 50-00-0 formaldehyd 
• 321-28-8 1-fluoro-2-methoxybenzene 

Relevant articles and documents

3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel

Bedaquiline is a new drug of the diarylquinoline class that has proven to be clinically effective against drug-resistant tuberculosis, but has a cardiac liability (prolongation of the QT interval) due to its potent inhibition of the cardiac potassium channel protein hERG. Bedaquiline is highly lipophilic and has an extremely long terminal half-life, so has the potential for more-than-desired accumulation in tissues during the relatively long treatment durations required to cure TB. The present work is part of a program that seeks to identify a diarylquinoline that is as potent as bedaquiline against Mycobacterium tuberculosis, with lower lipophilicity, higher clearance, and lower risk for QT prolongation. Previous work led to the identification of compounds with greatly-reduced lipophilicity compounds that retain good anti-tubercular activity in vitro and in mouse models of TB, but has not addressed the hERG blockade. We now present compounds where the C-unit naphthalene is replaced by a 3,5-dialkoxy-4-pyridyl, demonstrate more potent in vitro and in vivo anti-tubercular activity, with greatly attenuated hERG blockade. Two examples of this series are in preclinical development.

ANTIBACTERIAL COMPOUNDS AND USES THEREOF

The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.

Synthesis and Biological Evaluation of 1,2,3-triazole tethered Pyrazoline and Chalcone Derivatives

A series of pyrazoline derivatives and corresponding chalcone intermediates with substituents same as combretastatin-A4(CA-4) conjugated with triazole nucleus has been synthesized and evaluated for their anticancer potential. Sulphorhodamine B(SRB) assay indicated compound 12c to be the most active compound from the series with GI50 value of 6.7 μm against the human liver carcinoma cell line HepG2. Interestingly, the intermediate 11c exhibited more promising cytotoxicity demonstrating GI50 value of 1.3 μm against the prostate cancer cell line DU145. Compounds 11c and 12c caused accumulation of cells in G2/M phase and inhibited tubulin polymerization. Furthermore, these compounds reduce the mitochondrial membrane potential and activate caspases 3 and 9, thereby indicating their ability to trigger apoptosis.

Anti-tubercular agents. Part 8: Synthesis, antibacterial and antitubercular activity of 5-nitrofuran based 1,2,3-triazoles

A series of 5-nitrofuran-triazole conjugates were synthesized and evaluated for their antimicrobial activity against both Gram-positive and Gram-negative bacterial strains. All the compounds exhibited promising inhibition towards Gram-positive pathogenic strains, while mild inhibitory effects were observed towards Gram-negative bacterial strains. Some of the compounds 8a, 8b, 8e, 8f, 8h are most active among the series exhibiting MIC value of 1.17 μg/ml against different bacterial strains. The bactericidal activity is found to be in accordance with the bacterial growth inhibition data. Compound 8e was found to be equipotent to the standard drug Ciprofloxacin displaying MBC value of 1.17 μg/ml against the bacterial strain Bacillus subtilis. The compounds have also demonstrated promising antibacterial activity against the resistant strain MRSA and were found to be effective inhibitors of biofilm formation. The compound 8b exhibited excellent anti-biofilm activity with IC50 value as low as 0.8 μg/ml. These conjugates were also screened for antitubercular activity against Mycobacterium tuberculosis H37Rv strain. Compound 8e showed promising antitubercular activity with MIC value of 0.25 μg/ml. Most of these compounds are less toxic to normal mammalian cells than the widely used antibacterial drug Ciprofloxacin.

Imidazopyridinone derivatives and their use as phosphodiesterase inhibitors

A compound (Ia): wherein the variables are defined in the specification, its prodrug or a pharmaceutically acceptable salt thereof useful in the treatment of angina, hypertension etc.